Chong Kun Dang Pharmaceutical Total Liabilities
Chong Kun Dang Pharmaceutical total liabilities. Based on the latest financial reports, Chong Kun Dang Pharmaceutical (185750) has total liabilities worth ₩803.02 Billion KRW (≈ $544.20 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 185750 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Chong Kun Dang Pharmaceutical (2016–2025)
Total liabilities of Chong Kun Dang Pharmaceutical from 2016 to 2025. This chart illustrates how Chong Kun Dang Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Chong Kun Dang Pharmaceutical to see how much of total assets are deployed in long-term investments.
Chong Kun Dang Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Chong Kun Dang Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shinsung Delta Tech Co.Ltd
KQ:065350
|
Korea | ₩605.30 Billion |
|
Sinoma Energy Conservation Ltd
SHG:603126
|
China | CN¥3.08 Billion |
|
Ur Energy Inc
NYSE MKT:URG
|
USA | $80.27 Million |
|
PDS Limited
NSE:PDSL
|
India | Rs-18.59 Billion |
|
E&R Engineering
TWO:8027
|
Taiwan | NT$1.49 Billion |
|
Korla Pear
SHG:600506
|
China | CN¥1.23 Billion |
|
Delixi Xinjiang Transp Co Ltd
SHG:603032
|
China | CN¥384.50 Million |
|
Nanjing Vishee Medical Technology Co Ltd
SHG:688580
|
China | CN¥103.07 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Chong Kun Dang Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 185750 current and non-current assets.
Liquidity & Leverage Metrics
Chong Kun Dang Pharmaceutical Total Liabilities Ratios Explained
Chong Kun Dang Pharmaceutical total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chong Kun Dang Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chong Kun Dang Pharmaceutical (2016–2025)
The table below shows the annual total liabilities of Chong Kun Dang Pharmaceutical from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩793.94 Billion ≈ $538.04 Million |
+41.17% |
| 2024-12-31 | ₩562.39 Billion ≈ $381.12 Million |
-4.16% |
| 2023-12-31 | ₩586.79 Billion ≈ $397.66 Million |
+16.52% |
| 2022-12-31 | ₩503.59 Billion ≈ $341.28 Million |
+4.72% |
| 2021-12-31 | ₩480.89 Billion ≈ $325.89 Million |
+21.82% |
| 2020-12-31 | ₩394.74 Billion ≈ $267.51 Million |
+20.94% |
| 2019-12-31 | ₩326.40 Billion ≈ $221.20 Million |
+16.32% |
| 2018-12-31 | ₩280.60 Billion ≈ $190.16 Million |
+2.44% |
| 2017-12-31 | ₩273.91 Billion ≈ $185.63 Million |
-4.71% |
| 2016-12-31 | ₩287.45 Billion ≈ $194.80 Million |
-- |
About Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally. It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health supplements. The company was founded in… Read more